Dose expansion cohort of a phase I trial of M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC).

Elizabeth R. Plummer,Natalie Cook,Hendrik-Tobias Arkenau,Jason M. Melear,Charles H. Redfern,Alexander I. Spira,Ki Y Chung,Geoffrey I. Shapiro,Tufia C. Haddad,Suresh S. Ramalingam,Robert Wesolowski,Thomas Goddemeier,Martin H. Falk,Emma Dean

Dose expansion cohort of a phase I trial of M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC).

2018

Elizabeth R. Plummer
Natalie Cook
Hendrik-Tobias Arkenau
Jason M. Melear
Charles H. Redfern
Alexander I. Spira
Ki Y Chung
Geoffrey I. Shapiro
Tufia C. Haddad
Suresh S. Ramalingam
Robert Wesolowski
Thomas Goddemeier
Martin H. Falk
Emma Dean

e21048Background: Ataxia telangiectasia and Rad3-related protein (ATR) is an essential regulator of the DNA damage response and is required for the survival of proliferating cells. DNA-damaging age...

Keywords:

non-small cell lung cancer (NSCLC)
Cohort
Pathology
Cancer research
Gemcitabine
Medicine
in patient
Ataxia-telangiectasia
DNA damage
Regulator

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations